PURPOSE: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in BIRC4 was originally described in male patients with X-linked lymphoproliferative syndrome type 2 (XLP2). Recent observations have highlighted a critical role of XIAP for the regulation of NOD2 signaling and are probably the molecular basis for increasingly recognized further immune dysregulatory symptoms of XIAP deficient patients, such as inflammatory bowel disease (IBD). We describe a large Caucasian family in which IBD and erythema nodosum (EN) also manifested in female carriers of XIAP mutations. METHODS: Clinical data and laboratory findings including flow cytometric analysis of XIAP protein expression and sequencing of the BIRC4 gene. NOD2 signaling was investigated by determination of TNFα production in monocytes upon L18-MDP stimulation in vitro. RESULTS: The BIRC4 nonsense mutation p.P225SfsX226 was identified as the genetic cause of XIAP deficiency in our family. Surprisingly, clinical symptoms were not restricted to male patients, but also occurred in several female carriers. The most severely affected carrier demonstrated random X-inactivation, leading to a significant expression of mutated XIAP protein in monocytes, and consequently to impaired NOD2 responses in vitro. CONCLUSION: Our report provides further evidence that clinical symptoms of XIAP deficiency are not restricted to male patients. Random X-inactivation may be associated with EN and mild IBD also in female carriers of BIRC4 mutations. Analysis of the X-inactivation pattern reflected by XIAP protein expression can identify such carriers and the analysis of NOD2 signaling by flow cytometry can confirm the functional significance. XIAP expression patterns should be investigated in female patients with a family history of EN and/or IBD.
PURPOSE: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in BIRC4 was originally described in male patients with X-linked lymphoproliferative syndrome type 2 (XLP2). Recent observations have highlighted a critical role of XIAP for the regulation of NOD2 signaling and are probably the molecular basis for increasingly recognized further immune dysregulatory symptoms of XIAP deficientpatients, such as inflammatory bowel disease (IBD). We describe a large Caucasian family in which IBD and erythema nodosum (EN) also manifested in female carriers of XIAP mutations. METHODS: Clinical data and laboratory findings including flow cytometric analysis of XIAP protein expression and sequencing of the BIRC4 gene. NOD2 signaling was investigated by determination of TNFα production in monocytes upon L18-MDP stimulation in vitro. RESULTS: The BIRC4 nonsense mutation p.P225SfsX226 was identified as the genetic cause of XIAP deficiency in our family. Surprisingly, clinical symptoms were not restricted to male patients, but also occurred in several female carriers. The most severely affected carrier demonstrated random X-inactivation, leading to a significant expression of mutated XIAP protein in monocytes, and consequently to impaired NOD2 responses in vitro. CONCLUSION: Our report provides further evidence that clinical symptoms of XIAP deficiency are not restricted to male patients. Random X-inactivation may be associated with EN and mild IBD also in female carriers of BIRC4 mutations. Analysis of the X-inactivation pattern reflected by XIAP protein expression can identify such carriers and the analysis of NOD2 signaling by flow cytometry can confirm the functional significance. XIAP expression patterns should be investigated in female patients with a family history of EN and/or IBD.
Authors: Rebecca A Marsh; Lisa Madden; Brenda J Kitchen; Rajen Mody; Brad McClimon; Michael B Jordan; Jack J Bleesing; Kejian Zhang; Alexandra H Filipovich Journal: Blood Date: 2010-05-20 Impact factor: 22.113
Authors: S Ammann; R Elling; M Gyrd-Hansen; G Dückers; R Bredius; S O Burns; J D M Edgar; A Worth; H Brandau; K Warnatz; U Zur Stadt; P Hasselblatt; K Schwarz; S Ehl; C Speckmann Journal: Clin Exp Immunol Date: 2014-06 Impact factor: 4.330
Authors: Yvonne Zeissig; Britt-Sabina Petersen; Snezana Milutinovic; Esther Bosse; Gabriele Mayr; Kenneth Peuker; Jelka Hartwig; Andreas Keller; Martina Kohl; Martin W Laass; Susanne Billmann-Born; Heide Brandau; Alfred C Feller; Christoph Röcken; Martin Schrappe; Philip Rosenstiel; John C Reed; Stefan Schreiber; Andre Franke; Sebastian Zeissig Journal: Gut Date: 2014-02-26 Impact factor: 23.059
Authors: C Speckmann; K Lehmberg; M H Albert; R B Damgaard; M Fritsch; M Gyrd-Hansen; A Rensing-Ehl; T Vraetz; B Grimbacher; U Salzer; I Fuchs; H Ufheil; B H Belohradsky; A Hassan; C M Cale; M Elawad; B Strahm; S Schibli; M Lauten; M Kohl; J J Meerpohl; B Rodeck; R Kolb; W Eberl; J Soerensen; H von Bernuth; M Lorenz; K Schwarz; U Zur Stadt; S Ehl Journal: Clin Immunol Date: 2013-07-31 Impact factor: 3.969
Authors: Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott Journal: J Biol Chem Date: 2017-04-12 Impact factor: 5.157
Authors: Asama Lekbua; Jodie Ouahed; Amy E O'Connell; Stacy A Kahn; Jeffrey D Goldsmith; Toshihiko Imamura; Christine N Duncan; Judith R Kelsen; Elizabeth Worthey; Scott B Snapper; Samir Softic Journal: J Pediatr Gastroenterol Nutr Date: 2019-07 Impact factor: 2.839
Authors: Cathal L Steele; Matthew Doré; Sandra Ammann; Maurice Loughrey; Angeles Montero; Siobhan O Burns; Emma C Morris; Bobby Gaspar; Kimberly Gilmour; Shahnaz Bibi; Hiba Shendi; Lisa Devlin; Carsten Speckmann; David M Edgar Journal: J Clin Immunol Date: 2016-08-05 Impact factor: 8.317